Bristol-Myers Squibb Company
BMY
NYSE72.45
Bristol-Myers Squibb Company
NYSE:BMY
RECENT
PRICE
72.45
P/E
RATIO
23.60
(PEG:0.13)
P/E RATIO
RELATIVE
TO S&P
1.19
DIV
YLD
2.89%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
- - Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 01/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
9.14
0.81
0.66
1.12
9.82
1.10
1.17
1.12
10.42
2.65
1.40
1.24
9.53
5.38
1.69
1.26
11.37
1.81
2.37
1.29
12.50
2.18
2.63
1.33
10.55
1.17
3.83
1.37
9.97
1.56
1.83
1.40
9.58
1.21
1.58
1.45
9.93
0.94
0.61
1.49
11.63
2.67
0.98
1.52
12.63
0.61
2.57
1.57
13.82
3.01
3.06
1.60
15.33
2.02
4.24
1.57
18.83
(3.99)
5.89
1.80
21.54
3.25
7.08
2.04
21.83
3.12
5.94
2.14
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.40
5.10
0.43
5.36
0.48
6.19
0.37
7.52
0.25
9.17
0.22
9.39
0.33
8.16
0.33
9.22
0.32
8.96
0.49
8.56
0.73
9.68
0.64
7.14
0.58
8.59
0.49
30.26
0.33
16.75
0.45
16.70
0.51
15.50
CAPEX per share
Book Value per share
1,960
1,970
1,977
1,974
1,713
1,700
1,670
1,644
1,657
1,667
1,671
1,645
1,633
1,705
2,258
2,153
2,141
Comm.Shares outs.(m)
- -
- -
- -
26.1
1.5
3.9%
8.1
0.4
5.8%
4.0
0.1
5.8%
14.1
0.7
5.0%
13.2
0.8
4.6%
28.5
1.9
4.1%
28.2
1.7
3.2%
43.3
2.4
2.8%
68.3
3.4
2.3%
23.8
1.1
2.4%
93.6
4.0
2.7%
19.1
0.8
2.8%
24.9
1.0
3.1%
(15.1)
(0.4)
3.0%
19.4
0.6
3.2%
23.6
1.2
2.9%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (30/9/22 | Q3)
Total liabilities
$65,462 m.
Total assets
$98,196 m.
Long-term debt
$36,966 m.
Cash and equiv.
$7,734 m.
Goodwill $21,112 m.
Retained earnings $24,675 m.
Common stock 2,133 m. shares
Market Capitalisation
$154,040 m. (as of 29/1/23)
21,244
31.3%
17,621
22.3%
16,385
17.9%
15,879
10.8%
16,560
10.4%
19,427
23.4%
20,776
16.6%
22,561
22.7%
26,145
22.6%
42,518
5.1%
46,385
15.9%
46,738
20.9%
Revenue (m)
Operating margin
801
3,709
681
1,960
763
2,563
467
2,004
376
1,565
382
4,457
789
1,007
637
4,920
1,746
3,439
10,380
(9,015)
10,686
6,994
10,334
6,677
Depreciation (m)
Net profit (m)
24.7%
17.5%
(6.9)%
11.1%
10.8%
15.6%
14.8%
12.6%
21.5%
9.5%
23.8%
22.9%
81.0%
4.8%
17.1%
21.8%
30.5%
13.2%
(30.9)%
(21.2)%
13.4%
15.1%
12.6%
14.3%
Income tax rate
Net profit margin
7,538
5,376
15,956
1,242
6,568
13,623
6,476
7,981
15,154
6,147
7,242
14,852
2,398
6,550
14,266
4,863
5,716
16,177
5,291
6,975
11,741
6,506
5,646
14,031
11,050
44,059
51,598
11,112
49,169
37,822
11,394
40,479
35,946
7,866
36,966
32,671
Working capital (m)
Long-term debt (m)
Equity (m)
16.6%
16.9%
23.2%
7.7%
5.5%
14.4%
10.5%
8.0%
16.9%
8.7%
7.6%
13.5%
7.3%
6.9%
11.0%
18.6%
18.0%
27.6%
4.3%
16.0%
8.6%
20.9%
17.6%
35.1%
3.5%
4.3%
6.7%
(7.2)%
(4.6)%
(23.8)%
9.3%
8.6%
19.5%
9.6%
8.8%
20.4%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
15,393
17,593
17,026
Receivables
7,685
8,501
12,516
Inventory
4,293
2,074
2,095
Other
1,983
3,167
1,430
Current assets
29,354
30,192
33,262
Acc. Payable
2,445
2,713
2,949
Debt due
3,479
2,504
5,117
Other
12,380
13,863
13,802
Current liab.
18,304
19,080
21,868
57.1%
64.3%
8.6%
66.1%
10.5%
72.4%
(18.2)%
80.5%
(51.9)%
218.5%
43.5%
158.8%
(164.3)%
119.6%
47.2%
58.8%
22.6%
138.0%
145.3%
- -
37.3%
70.1%
31.4%
101.6%
Plowback ratio
Div.&Repurch. to FCF
Bristol-Myers Squibb Company (US) started trading on July 5, 1929 (cik: 0000014272), operates in the Healthcare sector (Drug Manufacturers—General industry), has 32,200 full-time employees, and is led by Dr. Giovanni Caforio. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
24.05%
12.74%
Cash flow
40.41%
28.23%
Earnings
-45.31%
-9.65%
Dividends
15.98%
8.45%
Book value
63.90%
27.43%
Insider trading
Type
Shares
Date
Haller Julia A
Award
469
12/31/22
Rice Derica W
Award
504
12/31/22
Storch Gerald L
Award
504
12/31/22
Bhatt Deepak
Award
104
12/31/22
Samuels Theodore R. Ii
Award
678
12/31/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
10,781
10,129
10,540
11,068
42,518
2021
11,073
11,703
11,624
11,985
46,385
2022
11,648
11,887
11,218
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
(0.34)
(0.04)
0.83
(4.44)
-3.99
2021
0.94
0.49
0.72
1.10
3.25
2022
0.60
0.67
0.75
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.45
0.45
0.45
0.45
1.80
2021
0.51
0.51
0.51
0.51
2.04
2022
0.55
0.54
0.54
- -
- -
07/26/2022
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market
The Wall Street Journal - Read more...
06/03/2022
Bristol-Myers to Buy Turning Point Therapeutics for $4.1 Billion
The Wall Street Journal - Read more...
04/29/2022
FDA Approves New Bristol-Myers Drug for Common Inherited Heart Disease
The Wall Street Journal - Read more...